Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$1.10

52W Range

$0.28 - $2.39

50D Avg

$0.85

200D Avg

$0.84

Market Cap

$395.86M

Avg Vol (3M)

$4.36M

Beta

1.14

Div Yield

-

LXRX Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

103

IPO Date

Apr 07, 2000

Website

LXRX Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24
Reportable Segment	$31.08M

Fiscal year ends in Dec 24 | Currency in USD

LXRX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$31.08M	$1.20M	$139.00K
Operating Income	$-197.12M	$-171.75M	$-100.76M
Net Income	$-200.40M	$-177.12M	$-103.13M
EBITDA	$-197.12M	$-163.46M	$-98.74M
Basic EPS	$-0.63	$-0.80	$-0.62
Diluted EPS	$-0.63	$-0.80	$-0.62

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 13, 25 | 5:00 PM

Q4 24Mar 06, 25 | 5:00 PM

Q3 24Nov 12, 24 | 5:51 PM

Peer Comparison

Ticker	Company
RIGL	Rigel Pharmaceuticals, Inc.
FOLD	Amicus Therapeutics, Inc.
CRIS	Curis, Inc.
PDSB	PDS Biotechnology Corporation
ATYR	aTyr Pharma, Inc.
ELEV	Elevation Oncology, Inc.